Hemostatic/fibrinolytic predictors of allograft coronary artery disease after cardiac transplantation.

Allograft coronary artery disease (CAD) remains the leading cause of morbidity and mortality affecting the long-term survival of patients after cardiac transplantation. Because there is increasing evidence that imbalances in hemostatic and fibrinolytic pathways are associated with graft failure, we hypothesized that atherothrombotic risk factors may contribute to allograft CAD. This study sought to determine if plasma hemostatic and fibrinolytic parameters are associated with the severity of allograft CAD. The extent of allograft CAD was investigated by angiography and intravascular ultrasound (IVUS) in 16 cardiac transplant recipients. Intimal thickening was quantified using IVUS by measuring the intimal index (li = intimal area/[intimal area + luminal area]) in two to five segments of the left anterior descending (LAD) coronary artery. The maximal li per patient was calculated and index to the time post-transplant (Mxli/Yr). Plasma fibrinogen (FGN), tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1), lipoprotein(a) (Lp(a)), and net fibrinolytic activity of plasma were assayed 6-24 months after transplant as indicators of the fibrinolytic system and then correlated with the IVUS measurements. The FGN level correlated with the severity of intimal thickening, Mxli/Yr (r2 = 0.41, p = 0.008), and was inversely correlated with angiographic tertiary vessel filling (r2 = 0.25, p = 0.051). In patients with lower plasma fibrinolytic activity (lytic zone less than 100 mm2), Mxli/Yr was increased eightfold (0.218 +/- 0.137 versus 0.025 +/- 0.021, p = 0.001). t-PA (r2 = 0.0004, p = 0.94), PAI-1 (r2 = 0.008, p = 0.75) and Lp(a) levels (r2 = 0.11, p = 0.21) did not predict Mxli/Yr. Thus, we demonstrate that plasma FGN and net fibrinolytic activity correlate with the degree of intimal thickening measured by IVUS after cardiac transplantation. These data suggest that fibrin deposition may play a role in allograft CAD after cardiac transplantation.

Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators.

BACKGROUND: Heparin is often administered during and after coronary angioplasty to prevent closure of the dilated vessel. However, ischemic or hemorrhagic complications occur in 5 to 10 percent of treated patients. We studied whether these complications could be prevented when the direct thrombin inhibitor bivalirudin (Hirulog) was used in place of heparin. METHODS: We performed a double-blind, randomized trial in 4098 patients undergoing angioplasty for unstable or postinfarction angina. Patients were assigned to receive either heparin or bivalirudin immediately before angioplasty. The primary end point were death in the hospital, myocardial infarction, abrupt vessel closure, or rapid clinical deterioration of cardiac origin. RESULTS: In the total study group, bivalirudin did not significantly reduce the incidence of the primary end point (11.4 percent, vs. 12.2 percent for heparin) but did result in a lower incidence of bleeding (3.8 percent vs. 9.8 percent, P < 0.001). In the prospectively stratified subgroup of 704 patients with postinfarction angina, bivalirudin therapy resulted in a lower incidence of the primary end point (9.1 percent vs. 14.2 percent, P = 0.04) and a lower incidence of bleeding (3.0 percent vs. 11.1 percent, P < 0.001), but in a similar cumulative rate of death, myocardial infarction, and repeated revascularization in the six months after angioplasty (20.5 percent vs. 25.1 percent, P = 0.17). CONCLUSIONS: Bivalirudin was at least as effective as high-dose heparin in preventing ischemic complications in patients who underwent angioplasty for unstable angina, and it carried a lower risk of bleeding. Bivalirudin, as compared with heparin, reduced the risk of immediate ischemic complications in patients with postinfarction angina, but this difference was no longer apparent after six months.

Myocardial fibrosis in endomyocardial biopsy specimens: do different bioptomes affect estimation?

Estimation of fibrosis in endomyocardial biopsy specimens (EMB) is integral to their assessment; typically, EMB fibrosis is assessed qualitatively. We quantitated percent fibrosis in 697 paraffin-embedded, Masson's trichrome stained EMB taken from 6 sites along the right ventricular septum and from 1 site in the left ventricular free wall, utilizing Caves-Schultz (C-S) and Cordis (C) bioptomes and a scalpel in 34 formaldehyde-fixed autopsy hearts, 22 of which were anatomically normal (AN) and 7 of which were idiopathically dilated. Total tissue area and area of fibrosis were quantitated by computer-based image analysis. The mean total areas as obtained by the C-S and C bioptomes and scalpel were 0.0535 cm2 (+/- 0.028), 0.0338 cm2 (+/- 0.020), and 0.4370 cm2 (+/- 0.144), respectively. The C-S and C bioptomes and the scalpel from all hearts yielded percent fibrosis of 10.6, 12.3, and 5.4, respectively. The AN hearts had percents of 9.3, 11.8, and 4.5, while the ID hearts had 11.0, 13.7, and 7.3% fibrosis, respectively, by each sampling method. A consistent pattern was observed: the larger the piece of endomyocardium, i.e., scalpel greater than CS greater than C, the lesser the quantitated percent fibrosis. Thus, beyond allowing for biological variability in the degree of endomyocardial fibrosis, the impact of EMB size and the biotome type must be accommodated in qualitative surgical reports pertaining to myopathic hearts.